Diabetes
From the Journals
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
Only 9% of eligible adults with T2D received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, in a new analysis.
Opinion
Toxic chemicals we consume without knowing it
“A grossly underappreciated driver in what ails us is the role of environmental toxins and endocrine-disrupting chemicals.”
From the Journals
Irregular sleep tied to markers of atherosclerosis
‘Poor sleep is linked with several cardiovascular conditions.’
Conference Coverage
Therapy app cut A1c, drug intensification in T2D
From the Journals
Real-time CGM plus insulin pump best for type 1 diabetes
Real-time continuous glucose monitoring and insulin pump use yielded more time in target glucose range vs. intermittently scanned CGM and...
Livin' on the MDedge
A purple warrior rises in the battle against diabetes
Plus: Rare honey builds strong but bacteria-prone bone implants, and mycoprotein builds strong gut microbiomes.
Conference Coverage
Metformin linked to reductions in COVID-19 viral load
Key questions the findings raise include whether the results correlate with clinical outcomes or transmission, and whether the findings are...
Latest News
Are ‘Momi Pods’ the future of postnatal care?
The program allows moms to book regular checkups for their baby, and then a follow-up appointment immediately after for themselves.
Feature
How to get started with prescribing and advising on CGM
Continuous glucose monitoring is gaining ground with both patients and providers because of an array of driving forces.
From the Journals
Diabetes drug tied to lower dementia risk
Risk for dementia is doubled in adults with T2DM, say the authors of a new paper.
From the Journals
COVID-19 shot appears to reduce diabetes risk, even after Omicron
Several studies conducted early in the pandemic suggested increased risks for both new-onset diabetes and cardiometabolic diseases following COVID...